MounzerEAghaMD

Hematology • Pittsburgh, PA

Hematologic Oncology

Director, Mario Lemieux Center for Blood Cancers

Join to view full profile

Dr. Agha is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Agha's full profile

Already have an account?

Office
5115 Centre Ave
3rd Floor
Pittsburgh, PA 15232
Phone+1 412-864-6648

Fax+1 412-864-6666

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 1989 - 1992
Penn State Milton S Hershey Medical CenterResidency, Internal Medicine, 1986 - 1989
University of Aleppo Faculty of MedicineClass of 1983

Certifications & Licensure

PA State Medical License 1987 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology

Clinical Trials

Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201) Start of enrollment: 2004 Jan 01
Completed
Phase 3
Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202) Start of enrollment: 2004 Aug 01
Terminated
Phase 2, Phase 3
Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia Start of enrollment: 2008 Sep 01
Terminated
Phase 1
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 Start of enrollment: 2010 Oct 01
Active, not recruiting
Phase 3
Phase II Clofarabine and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2013 Oct 01
Terminated
Phase 2
Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source Start of enrollment: 2015 Feb 11
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

688 citations
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CART...
Jesus G. Berdeja, Deepu Madduri, Saad Z. Usmani, Andrzej Jakubowiak, Mounzer Agha
Lancet. 2021-07-24
218 citations
Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Fol...
Thomas Martin, Saad Z Usmani, Jesus G Berdeja, Mounzer Agha, Adam D Cohen
Journal of Clinical Oncology. 2023-02-20
103 citations
Intractable Coronavirus Disease 2019 (COVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication in a Chimeric Antigen Receptor-M...
Matthew K Hensley, William Bain, Jana L. Jacobs, Sham Nambulli, Urvi M. Parikh
Clinical Infectious Diseases. 2021-08-02

Authored Content

Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-cell Maturation Antigen–Directed Chimeric Antigen Receptor T Cell Therapy, in Patients with Relapsed/Refractory Multiple MyelomaDecember 2021

Press Mentions

Who Qualifies for a Coronavirus Booster Shot? Why It’s Still UnclearAugust 13th, 2021
Protecting the Immune-Compromised Keeps Everyone SafeAugust 5th, 2021
The Complex Situation for Immunocompromised People and COVID-19 VaccinesJune 16th, 2021
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member